Test Price
2,800 AED✅ Home Collection Available
ACADSB Gene 2‑Methylbutyrylglycinuria Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين ACADSB لمرض بيلة 2‑ميثيل بيوتيريل جليسين في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
يقدم هذا التحليل الجيني المتقدم فحصاً شاملاً للطفرات في جين ACADSB المرتبطة بمرض بيلة 2‑ميثيل بيوتيريل جليسين، وهو اضطراب استقلابي نادر. يُجرى وفق أعلى معايير الجودة العالمية وباعتماد هيئة الصحة بدبي، مما يضمن دقة التشخيص وسلامة المريض.
Test Overview
The ACADSB gene test sequences the entire coding region to identify pathogenic variants causing 2‑methylbutyrylglycinuria, a rare autosomal recessive disorder of branched‑chain amino acid metabolism. (تحليل جين ACADSB يكشف الطفرات المسببة لبيلة 2‑ميثيل بيوتيريل جليسين، وهو مرض استقلابي وراثي نادر).
| Feature | Our Test (ACADSB NGS) | Closest Alternative (Targeted Variant Panel) |
|---|---|---|
| Methodology | Full gene Next‑Generation Sequencing + CNV analysis | Limited panel of known mutations |
| Diagnostic Sensitivity | >99.9% (misses few deep intronic variants) | ~80–85% (misses novel/rare variants) |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks |
| Clinical Utility | Confirms diagnosis, carrier screening, family planning | Only rule‑in common mutations; often requires reflex to full sequencing |
| Price | 2800 AED | 1500 – 2000 AED |
Physician Insight & Safety Protocol
“As a DHA‑licensed clinical pathologist (DHA: 61713011), I underscore that the ACADSB NGS test is a powerful tool, but results must always be interpreted alongside biochemical markers and clinical phenotype. A positive variant does not always predict disease severity; conversely, a negative result may not exclude all possible metabolic disorders. Therefore, post‑test genetic counselling and clinical correlation are indispensable.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
⚠️ Medication Warning:
Do not discontinue or modify any prescribed medication, dietary supplements, or metabolic formula without direct consultation with your treating physician. Genetic results alone do not constitute a treatment directive.
Patient Safety & Exclusion Criteria
- Unresolved acute illness or metabolic crisis at the time of sample collection.
- Inability to provide informed consent (including from a legal guardian for minors under 18 years per CDS Law 2026).
- Pregnancy or active fertility planning without prior genetic counselling.
- Lack of a pre‑test genetic counselling session (mandatory for pedigree‑based risk assessment).
🚨 Emergency Red Flags:
Seek immediate medical attention if you experience recurrent vomiting, unexplained lethargy, seizures, hypotonia, or signs of metabolic acidosis (deep, rapid breathing) – these may indicate an acute metabolic decompensation.
UAE Regulatory & Quality Compliance
- Performed under the governance of Federal Decree‑Law No. 41 of 2024, Article 87 (genomic data privacy & clinical validity).
- Strict adherence to CDS Law 2026 (informed consent for minors and vulnerable populations).
- Data protection aligned with UAE PDPL – all results are encrypted and processed within the UAE.
- Laboratory accredited ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) – ensuring internationally recognised quality management.
Patient FAQ & Clinical Guidance
1. What is the ACADSB gene test?
The ACADSB gene test detects pathogenic variants in ACADSB causing 2‑methylbutyrylglycinuria, a treatable metabolic condition. This NGS‑based assay screens the entire coding sequence and exon‑intron boundaries, identifying missense, nonsense, splice‑site variants, and copy number changes. Results assist in confirming a clinical diagnosis, carrier detection, and preconception planning.
يكشف تحليل جين ACADSB عن الطفرات المسببة لبيلة 2‑ميثيل بيوتيريل جليسين، وهو اضطراب استقلابي قابل للعلاج. يشمل الفحص كامل التسلسل الترميزي والمناطق المحيطة بالإنترونات لكشف التغيرات المرضية.
2. Do I need a doctor’s referral for this test?
You can self‑order this test without a doctor's referral and receive a comprehensive, physician‑authored report. Our DHA‑licensed clinical team will review your health questionnaire and triage the request. The final report is validated by a board‑certified geneticist and includes actionable recommendations. A referral is recommended but not mandatory.
يمكنك طلب هذا الاختبار ذاتياً دون إحالة طبية، وستتلقى تقريراً شاملاً موقّعاً من طبيب مختص. ومع ذلك، يُفضّل وجود إحالة لضمان الاستفادة المثلى.
3. How long do results take and how will I receive them?
Results are available in 3–4 weeks via secure portal with integrated telephonic clinical interpretation support. Your genetic report is uploaded to an encrypted patient portal; you will be notified by SMS/WhatsApp. A 15‑minute telephonic interpretation session with a genetic counsellor is included to explain findings and next steps. Hard‑copy reports can be arranged upon request.
تظهر النتائج خلال ٣ إلى ٤ أسابيع عبر بوابة إلكترونية آمنة مع إمكانية جلسة تفسير هاتفية مع مستشار جيني. ستُبلغ عبر رسالة نصية لتحميل التقرير.
Relevant Specialist Referrals: This is commonly ordered by Medical Geneticists, Metabolic Disease Specialists, and General Physicians evaluating unexplained neurological symptoms, metabolic acidosis, or positive newborn screening results for 2‑methylbutyrylglycinuria. Direct patient access is available with tele‑support.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians